Primary progression at first tumor assessment, performed after two months of vemurafenib therapy, was linked with pretreatment plasma upregulation of 7SL and Zeb2NAT and downregulation of Zfas1 and AIR. The gene discussed is ZEB2-AS1; the disease is neoplasm.